Page 27 - 10 Most Trusted Diagnostic Companies in India 2022

FOCUS POINT

Some of the recent developments/ • In July 2021, Generic Health • In May 2021, Cipla launched of Oxygen Enrichment Unit (OEU).

investments in the Indian phar- (an Australia-based subsid- a real-time COVID-19 detec- The unit can deliver medical air in
maceutical sector are as follows: iary of Lupin Limited) signed an tion kit ‘ViraGen’ that is based the range of ~15 litres per minute,

• In November 2021, US-based agreement with Southern Cross on multiplex polymerase chain with oxygen purity of >90%. It trans-
Akston Biosciences announced Pharma Pty Ltd. (SCP). Under reaction (PCR) technology. ferred the technology to MSMEs—

that it will start the clinical trial of this deal, Lupin will acquire 100% Conquerent Control Systems Pvt.
its second-generation COVID-19 shares of SCP. The acquisition is • In May 2021, the Govern- Ltd., A B Elasto Products Pvt. Ltd.
vaccine ‘AKS-452’ in India soon. expected to further strengthen ment of India invited R&D and Automation Engineers, Mech

Lupin’s foothold in Australia. proposals on critical compo- Air Industries and Auto Malleable.
• In October 2021, Astra-

Zeneca India launched a Clinical • In July 2021, Generic Health nents and innovations in oxygen • In April 2021, National Pharma-
Data and Insights (CDI) division (an Australia-based subsid- concentrators by June 15, 2021 ceutical Pricing Authority (NPPA)
to further strengthen its global iary of Lupin Limited) signed an . fixed the price of 81 medicines

presence and manage data-re- • In May 2021, Indian Immunolog- including off-patent anti-dia-
lated aspects of its clinical trials agreement with Southern Cross icals Ltd. (IIL) and Bharat Immuno- betic drugs allowing due benefits
. Pharma Pty Ltd. (SCP). Under logicals and Biologicals Corpora- of patent expiry to the patients
• In September 2021, the this deal, Lupin will acquire 100% tion (BIBCOL) inked technology

Indian government contributed shares of SCP. The acquisition is transfer pacts with Bharat Biotech • In February 2021, Aurobindo
US$ 4 billion to the pharma- expected to further strengthen Pharma announced plans to procure
ceutical and medical industries. Lupin’s foothold in Australia. to develop the vaccine locally to solar power from two open access
boost India’s vaccination drive. The
• In August 2021, Glenmark collab- • In June 2021, Sun Pharmaceu- two PSUs plan to start production

orated with SaNOtize to introduce of vaccines by September 2021.
spray for COVID-19 treatment ticals acquired the patent license
in India and other Asian markets. for Dapagliflozin from Astra- • In May 2021, Eli Lilly & Company
Zeneca. The company will be

• In August 2021, Uniza Group, an distributing and promoting the issued non-exclusive volun-
Ahmedabad-based pharmaceu- drug under the brand name ‘Oxra’. tary licenses to pharmaceutical
tical firm, signed an agreement companies—Cipla Ltd., Lupin

with Lysulin Inc. (an US-based firm) • In June 2021, Lupin Ltd. Ltd., Natco Pharma & Sun Phar-
to introduce Lysulin, a nutritional announced its intention to enter maceutical Industries Ltd.—to
product for Indian consumers. the digital healthcare space in produce and distribute Barici-

• In August 2021, Alkem Labo- India. It incorporated Lupin Digital tinib, a drug for treating COVID-19.

ratories introduced Famotidine Health Ltd., a wholly owned subsid-
and Ibuprofen tablets to treat iary, to provide a digital therapeu- • In April 2021, the CSIR-

osteoarthritis and rheumatoid tics platform for medical practi- CMERI, Durgapur, indigenously
arthritis symptoms in the US. tioners and patients in the country. developed the technology

|26 thecorporatereview.com | India | Vol. 3 | Issue 3 | March 2022 |27